{"name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","slug":"dicerna-pharmaceuticals-inc-a-novo-nordisk-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DCR-PHXC","genericName":"DCR-PHXC","slug":"dcr-phxc","indication":"Phytanic acid storage disease (Refsum disease) or related lipid metabolism disorder","status":"phase_3"}]}],"pipeline":[{"name":"DCR-PHXC","genericName":"DCR-PHXC","slug":"dcr-phxc","phase":"phase_3","mechanism":"DCR-PHXC is an RNA interference therapeutic that silences the PHXC gene to reduce production of a disease-causing protein.","indications":["Phytanic acid storage disease (Refsum disease) or related lipid metabolism disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE80U1c4Szg1Sy0wSW16T0hFcURxQmQ1UDZpVjduR29ZanZ5MTFBNWlFbExkbmJ5b3pqS1FxcE1zYXZNdW9Ua3JMMmtjcFVnVVk0OHh2ckJ3dnVKSDBSTXYxRFhuZ25JSUVvSVlHbEYwdTY0LVFv?oc=5","date":"2026-01-12","type":"pipeline","source":"Market.us","summary":"Novo Nordisk Statistics and Facts - Market.us","headline":"Novo Nordisk Statistics and Facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcFhfdkFZMFhSTWdqTjNad1pHSU52TEZrR2JLTHM2RDBoQ1lNLU8yQ1FxVFZmYkNLSjNQZEpLdFFQMTBWWDR2MXk0bUJ4YzRMd2pWVDdBY1hid2VPZEN5ZjJOeTVYNmY5RlhZbV8tb3pnWWJ1eUZ1aXByQTNiYThNWGlhNDIzUkpqTmIxQWllRTcwRWVTb1lUeG9aUG9KbV9OTDdsNHJ1VFBybWRHeVdwc1hLOFRrWEUySk9LcFUwWk4?oc=5","date":"2025-08-28","type":"pipeline","source":"MedCity News","summary":"Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines - MedCity News","headline":"Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQUnY2ZjZBQjNMM3RZeThDU091WHJLRkFQU0ZKR2dDaVhBNDZPZGMyaHgtallPWkJkTDU5SUJjZ3N4RGY0c0FBbnVkSWYwanJzTXY0TUNCSG9nejRPTXRDSGQzZU8zUjV1aWZ2TE5vYmRaVWNTLXdLeUV3cDNMRk42NFhhRWYwZUtJWnhSVlFpWWw3aWdaRWtqRXN1VTRubHU3emVucFhMN1BNcWtPdkZxa2tR?oc=5","date":"2024-10-24","type":"pipeline","source":"BioSpace","summary":"Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs - BioSpace","headline":"Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5hd0Vlb0tHNXFnUkx5cDBkUEZmc3N6cnd3aF9mZmRhbWNTTkNoc3FIYlhQV2NydE93RmxqSDNyaHBtVmtvUFhhWEVheFNHSFhrWWxaZ1NveHVPc05DLUYta1pKbWM?oc=5","date":"2024-06-06","type":"pipeline","source":"Labiotech.eu","summary":"Eight biotech companies advancing the field of siRNA - Labiotech.eu","headline":"Eight biotech companies advancing the field of siRNA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE55bVBnQlBzTlYtQlZMN3c4V0pwMmlGaUUtY0hfR2xXa0V5U2ZHcEF3bktuOF9TN0tLU3NJT2MtMmo5S24ydjBPRlpqajduN1ZnbC1mM0MzRVZlWTQyN3JOUVo0QTBEZ2NoVklSUVA5Zw?oc=5","date":"2024-02-06","type":"pipeline","source":"medwatch.com","summary":"Novo Nordisk's USD 11bn factory purchase breaks firm's own record - medwatch.com","headline":"Novo Nordisk's USD 11bn factory purchase breaks firm's own record","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNeVF0SjU3ZWFjMWtDaUtKLXllVFFrU0wzNXpKNzJWNVgzRjFlREZZbTVNNEVKN2ZVbDM0ZWdNcDZfNFcyMTFxUWRjWlc3b1JleE96ajRDRHYyMXltR3Yxa2lhV1RZeFNKcHhFb2UtQjJ2M2dZNTFmRUwyaWs1amRVWUQ3czBMb3BNT2dkSVNHdnlBenpWdGlKWGlOYzRFa1N0N2JZcndJeTB1R1QtSDBka2RMU2dmb2M?oc=5","date":"2022-01-14","type":"pipeline","source":"BioPharma APAC","summary":"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - BioPharma APAC","headline":"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPdGVqSmVHQWdaSlVsdWNfMjhvWEprY0JPVDRxLUlRS2NFVmtSb2NRY2k2dmFlMmpOcmNpeHpzbklCbnVCZFdZZE1Nd2ZWSE1LMG9nZjRsRnZlSGZybTQxRGRFMVM2aVFzYlFQX2s2RUtMM3M2YmhjTkZyY244ZkpEMVhVaFROU3lMb3dwN1BFMDdSUGl4eUhIWHVJT1lORk8zT2Q1V2s1ZkQ3dzN6UmJVNEFDWnVVSXRwcDNDRERQLXd3Qk9yemU4Vg?oc=5","date":"2021-12-27","type":"pipeline","source":"Business Wire","summary":"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Business Wire","headline":"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOc3lPdDFyOW1kbHhtWGZQX1ByM09rVDNaVkpGdWI2RDE1MWEtakF6RktoNHRBcVJHT2VhWHlodmZMVGFIbW4xWE13bUlReDRUQ0o4ODJTbzNtS1IwU0pwWV8tUXI4bGJRNGhKUmRIY2dPZVRsb09yZnczbi05MEtwVE9lRGFLZw?oc=5","date":"2021-11-22","type":"regulatory","source":"CHEManager","summary":"Novo Nordisk Buys Dicerna Pharmaceuticals - CHEManager","headline":"Novo Nordisk Buys Dicerna Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdW5Rd2ZhTXh1dmZFRWE0UUIyVE1xWFJfU2FDSnd4WkU5eVE1R2lvWGxwUmlUcHFqRm5WT2p6RXQ2eG11QmxncXRCbUdDYnNmelNsMzlNY1hVUEdnenNBbEtyWUJBSC1GU2NzTlpTUGJLUlJVeEJFcW5NUWd6ODdpeE5OYTBnZE1rb2dNUXNkOEkybjhlS2s2a2JHanZIUHlBbVdudVotRi05QkdscDZla3pkSl9CMWdOY0VqMnVpdEI?oc=5","date":"2021-11-18","type":"deal","source":"Reuters","summary":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion - Reuters","headline":"Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5FeFprRGpjbldyaU1MRjV5M0FZc3RzQ0luUE5WUHFHZm9EekhkOGFUN0N6bkUxZF8tRnBqajhiYlFSZ2VleUxOa2libHhCSWhQOFhjdGtfQXRUeUVOMHVoX2VjeGlXZUIyUW1Gc29xWDBCNFpzVkJtWFFFQ3d0UQ?oc=5","date":"2021-11-18","type":"deal","source":"BioPharma Dive","summary":"Novo to acquire Dicerna for more than $3B amid RNA drug resurgence - BioPharma Dive","headline":"Novo to acquire Dicerna for more than $3B amid RNA drug resurgence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNREhtM3ZuZGlkdTMyN2JPWEFYNThDUTFQd01hOEl5LWRBUV90X25iT2Z1R0F3T3lxbjBYb0p3bVlGYVhqbWFoSUFyMzhwVzNmYUUzM0RzX2FKR2xKQ2dtY05jaU1OaEMwZlUzYmR2TUZXTnNUaTBnNXlkUDRZOHhnUy1DcVkyVUlHVDZv?oc=5","date":"2021-11-18","type":"deal","source":"Barron's","summary":"Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion - Barron's","headline":"Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBhTFg1bUtfZWVUZlltbFVXNHpKNjBNc01wU2o0NUNTcEFhY0hBNndrbmlNV0VzR3d5b2YzWnRSNHR6NUdJVjMyUFNQNHZvY3RJZzhtZjV1VjJfdHZGRkhXZV9GYzFvLVNOLUU1WA?oc=5","date":"2021-11-18","type":"pipeline","source":"Reuters","summary":"Dicerna Pharmaceuticals Inc - Reuters","headline":"Dicerna Pharmaceuticals Inc","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}